2. Search Result
Search Result
Isoforms Recommended: COX-2
Results for "

COX-2

" in MedChemExpress (MCE) Product Catalog:

919

Inhibitors & Agonists

2

Screening Libraries

6

Fluorescent Dyes

10

Biochemical Assay Reagents

4

Peptides

292

Natural
Products

2

Recombinant Proteins

111

Isotope-Labeled Compounds

11

Antibodies

6

Click Chemistry

12

Oligonucleotides

4

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14445
    FK 3311

    COX-2 Inhibitor V

    		 COX Inflammation/Immunology
    FK 3311 (COX-2 Inhibitor V) is a selective inhibitor of COX-2 with antiinflammatory agent.
    FK 3311
  • HY-149269
    COX-2-IN-30

    		COX Carbonic Anhydrase LOX-1 Inflammation/Immunology
    COX-2-IN-30 is a benzenesulfonamide derivative, as well as an orally active and dual inhibitor of COX (IC50=49 nM for COX-2, 10.4 μM for COX-1) and 5-LOX (IC50=2.4 μM). COX-2-IN-30 also inhibits transmembrane hCA IX and hCA XII isoform with nanomolar calss Ki values. COX-2-IN-30 exhibits analgesic, anti-inflammatory, and ulcerogenic activities, and does not show acute gastric effect .
    COX-2-IN-30
  • HY-171992
    COX-2-IN-55

    		VEGFR Caspase Calcium Channel Cancer
    COX-2-IN-55 (compound 1) is an orally active, Celecoxib (HY-14398)-based analog with broad-spectrum anticancer activity and weak COX-2 inhibition. COX-2-IN-55 specifically inhibits SERCA2, increases caspase-3 cleavage and DR5 levels, thereby activating GRP78 and inhibiting the development of triple-negative breast cancer (TNBC). COX-2-IN-55 can also downregulate the levels of angiogenic markers VEGF-α and IL-8, inhibiting the formation of microvessels .
    COX-2-IN-55
  • HY-116763
    COX-2/5-LOX-IN-4

    		COX LOX-1
    COX-2/5-LOX-IN-4 (Compound 1) is a dual inhibitor that acts on both COX-2 and 5-LOX, with IC50 values of 0.05 μM for COX-2 and 0.003 μM for 5-LOX. By inhibiting the arachidonic acid metabolism pathway, COX-2/5-LOX-IN-4 reduces the production of prostaglandins and leukotrienes, alleviating inflammatory responses. In a rat ear edema model, intravenous administration (0.01 and 0.1 mg/kg) reduced edema by 41% and 44%, respectively, demonstrating significant anti-inflammatory effects. COX-2/5-LOX-IN-4 shows promise for studying the mechanisms of inflammatory diseases .
    COX-2/5-LOX-IN-4
  • HY-101655
    COX-2-IN-2

    		COX Inflammation/Immunology
    COX-2-IN-2 is a selective and inducible COX2 inhibitor with an IC50 of 0.24 μM. COX-2-IN-1 is an anti-inflammatory compound with anti-inflammatory and analgesic activities.
    COX-2-IN-2
  • HY-113264
    PGD2 ethanolamide

    		Apoptosis Cancer
    PGD2 ethanolamide is the COX-2 dependent metabolite of Anandamide that induces apoptosis in colorectal carcinoma (CRC) cells .
    PGD2 ethanolamide
  • HY-D2297
    AIE-GA

    		Fluorescent Dye Others
    AIE-GA is a Golgi apparatus (GA) fluorescent probe (green channel: λex = 405 nm, λem = 500-700 nm). AIE-GA has a favourable binding ability to interact with COX-2. AIE-GA binds to the cyclooxygenase catalytic site of COX-2 .
    AIE-GA
  • HY-179125
    COX-2-IN-59

    		COX Bcl-2 Family Caspase Apoptosis Cancer
    COX-2-IN-59 is a potent and selective COX-2 inhibitor with an IC50 of 0.052 μM. COX-2-IN-59 exhibits 200-fold selectivity over COX-1 (IC50 = 11.16 μM). COX-2-IN-59 reduces COX-2 levels, induces cell cycle arrest, and triggers apoptosis by increasing Bax expression, decreasing Bcl-2 levels, and activating caspase-3. COX-2-IN-59 can be used for the research of colon cancer .
    COX-2-IN-59
  • HY-146370
    COX-2-IN-12

    		COX Inflammation/Immunology
    COX-2-IN-12 (compound 3b) is a potent and selective inhibitor of COX-2 with an IC50 of 19.98 μM. COX-2-IN-12 is an anti-inflammatory agent. COX-2-IN-12 shows safety in-vivo acute toxicity study .
    COX-2-IN-12
  • HY-178440
    EGFR/COX-2-IN-2

    		EGFR COX Apoptosis Inflammation/Immunology Cancer
    EGFR/COX-2-IN-2 (Compound 10a) is a dual inhibitor targeting epidermal growth factor receptor (EGFR) (IC50= 6.0 μM) and cyclooxygenase-2 (COX-2) (IC50=50 μM). EGFR/COX-2-IN-2 induces S-phase cell cycle arrest and apoptosis. EGFR/COX-2-IN-2 is promising for research of cancers and inflammation-related diseases .
    EGFR/COX-2-IN-2
  • HY-U00275
    COX-2-IN-1

    		COX Inflammation/Immunology
    COX-2-IN-1 is potent and slective COX-2 inhibitor with an IC50 of 3.9 μM.
    COX-2-IN-1
  • HY-150550
    COX-2-IN-26

    		COX Inflammation/Immunology
    COX-2-IN-26 is a potent, selective and orally active COX-2 inhibitor with IC50 values of 10.61, 0.067, 1.96 µM for COX-1, COX-2, 15-LOX, respectively. COX-2-IN-26 shows anti-inflammatory activity. COX-2-IN-26 shows gastrointestinal safety profile .
    COX-2-IN-26
  • HY-105304
    COX-2-IN-36

    		COX Inflammation/Immunology
    COX-2-IN-36 (compound 1) is a very potent and specific COX-2 inhibitor, with an IC50 of 0.4 μM [2].
    COX-2-IN-36
  • HY-147963
    COX-2-IN-24

    		COX Infection
    COX-2-IN-24 is an orally active inhibitor of COX-2 with IC50 value of 0.17 μM, shows anti-inflammatory and low ulcerogenic activities.
    COX-2-IN-24
  • HY-14445R
    FK 3311 (Standard)

    COX-2 Inhibitor V (Standard)

    		 COX Reference Standards Inflammation/Immunology
    FK 3311 (Standard) is the analytical standard of FK 3311. This product is intended for research and analytical applications. FK 3311 (COX-2 Inhibitor V) is a selective inhibitor of COX-2 with antiinflammatory agent.
    FK 3311 (Standard)
  • HY-115936
    COX-2-IN-9

    		COX Inflammation/Immunology
    COX-2-IN-9 (compound 7a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 10.17 uM. COX-2-IN-9 has higher COX-2 selectivity than Celecoxib. COX-2-IN-9 shows good in vivo anti-inflammatory and low ulcerogenic activity .
    COX-2-IN-9
  • HY-115934
    COX-2-IN-7

    		COX Inflammation/Immunology
    COX-2-IN-7 (compound 4a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 6.585 uM. COX-2-IN-7 has higher COX-2 selectivity than Celecoxib. COX-2-IN-7 shows good in vivo anti-inflammatory and low ulcerogenic activity .
    COX-2-IN-7
  • HY-115935
    COX-2-IN-8

    		COX Inflammation/Immunology
    COX-2-IN-8 (compound 6a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 6.585 uM. COX-2-IN-8 has higher COX-2 selectivity than Celecoxib. COX-2-IN-8 shows good in vivo anti-inflammatory and low ulcerogenic activity .
    COX-2-IN-8
  • HY-168070
    COX-2-IN-48

    		COX NF-κB NO Synthase Inflammation/Immunology
    COX-2-IN-48 (5-25), a COX-2 inhibitor with an IC50 of 51.7 nM for human COX-2, exerts anti-inflammatory and analgesic effects in various rodent models by inhibiting NF-κB pathway. COX-2-IN-48 (5-25) inhibits the degradation of IκB, the phosphorylation and nuclear translocation of NF-κB p65, and the expression of COX-2 and iNOS .
    COX-2-IN-48
  • HY-147961
    COX-2-IN-23

    		COX Inflammation/Immunology
    COX-2-IN-23 (compound 9a) is a selective COX-2 inhibitor with IC50 values of 0.28 and 20.14 μM for COX-2 and COX-1. COX-2-IN-23 has anti-inflammatory activity and low ulcerogenic activity.
    COX-2-IN-23
  • HY-162244
    COX-2-IN-40

    		COX Inflammation/Immunology
    COX-2-IN-40 (compound 17) is a COX-2 inhibitor with the IC50 of 14.86 μM. COX-2-IN-40 can be used for study of chronic pain .
    COX-2-IN-40
  • HY-161147
    COX-2-IN-37

    		COX Inflammation/Immunology
    COX-2-IN-37 (compound 11) is a potent and selective COX-2 inhibitor. COX-2-IN-37 has strong antioxidant activity with an IC50 of 33.0 μg/mL .
    COX-2-IN-37
  • HY-157578
    COX-2-IN-38

    		COX Inflammation/Immunology
    COX-2-IN-38 (compound 52*) is a potent inhibitor of COX-2, with the IC50 value of 79.4 nM .
    COX-2-IN-38
  • HY-157583
    COX-2-IN-39

    		COX Others
    COX-2-IN-39 (compound 44) is a potent inhibitor of COX-2, with the IC50 value of 0.4 nM .
    COX-2-IN-39
  • HY-156254
    COX-2-IN-35

    		COX Inflammation/Immunology
    COX-2-IN-35 (compound 7) is a selective COX-2 inhibitor with an IC50 of 4.37 nM. COX-2-IN-35 has anti-inflammatory activity .
    COX-2-IN-35
  • HY-145988
    COX-2-IN-11

    		COX Inflammation/Immunology
    COX-2-IN-11 (compound 7b2) is a potent and selective inhibitor of COX-2. COX-2-IN-11 has the potential for the research of inflammation diseases .
    COX-2-IN-11
  • HY-161994
    COX-2-IN-47

    		COX Inflammation/Immunology
    COX-2-IN-47 (compound 6c ) is a selective COX-2 inhibitor with IC50 value of 0.03 μM. COX-2-IN-47 has antiedema activity .
    COX-2-IN-47
  • HY-159562
    COX-2-IN-46

    		COX Inflammation/Immunology
    COX-2-IN-46 (compound 5m) is an anti-inflammatory agent with potent analgesic activity. COX-2-IN-46 exhibits a significant inhibitory effect on COX-2 (IC50=87.74 nM) .
    COX-2-IN-46
  • HY-146371
    COX-2-IN-13

    		COX Inflammation/Immunology
    COX-2-IN-13 (compound 13e) is a potent and selective inhibitor of COX-2 with an IC50 of 0.98 μM. COX-2-IN-13 is an anti-inflammatory agent. COX-2-IN-13 shows safety in-vivo acute toxicity study .
    COX-2-IN-13
  • HY-175637
    COX-2-IN-57

    		COX MyD88 Neurological Disease Inflammation/Immunology
    COX-2-IN-57 is an orally active COX-2 inhibitor with an IC50 value of 0.02 μM. COX-2-IN-57 reduces MyD88 expression and decreases serum levels of COX-2, PGE2, and COX-1 in Cisplatin (HY-17394)/radiation-induced neuropathy rat model. COX-2-IN-57 demonstrates superior antinociceptive efficacy in hot plate, cold allodynia, and Randall-Selitto tests, along with hepato-/renal protection. COX-2-IN-57 can be used for the study of inflammation .
    COX-2-IN-57
  • HY-174159
    COX-2-IN-54

    		COX Inflammation/Immunology
    COX-2-IN-54 (Compound 7y) is an orally active COX-2 inhibitor with an IC50 of 4.15 μM. COX-2-IN-54 has a strong protective effect against DSS-induced ulcerative colitis and can significantly reduce tissue damage. COX-2-IN-54 has anti-inflammatory activity .
    COX-2-IN-54
  • HY-146161
    COX-2/NO-IN-1

    		COX NO Synthase Inflammation/Immunology
    COX-2/NO-IN-1 is an orally active nitric oxide synthase (iNOS), COX-2 expression and NO (IC50 of 3.52 μM) inhibitor. COX-2/NO-IN-1 has anti-inflammatory effects .
    COX-2/NO-IN-1
  • HY-161266
    COX-2/NLRP3-IN-1

    		COX NOD-like Receptor (NLR) NF-κB Inflammation/Immunology
    COX-2/NLRP3-IN-1 (Compound 6k) is a COX-2/NLRP3 inhibitor with a IC50 of 1.53 μM for COX-2. COX-2/NLRP3-IN-1 exerts anti-inflammatory effects by inhibiting the NF-κB/NLRP3 signaling pathway .
    COX-2/NLRP3-IN-1
  • HY-149270
    COX-2-IN-31

    		COX Inflammation/Immunology
    COX-2-IN-31 (compound 7b) is an orally active and dual inhibitor of COX-2 (IC50=60 nM) and 5-LOX (IC50=1.9 μM). COX-2-IN-31 also inhibits transmembrane hCA IX(Ki=48.9 nM) and hCA XII(Ki=5.8 nM) activity. COX-2-IN-31 exhibits anti-inflammatory and analgesic activity .
    COX-2-IN-31
  • HY-147911
    COX-2/PI3K-IN-1

    		PI3K COX Inflammation/Immunology Cancer
    COX-2/PI3K-IN-1 (compound 5d) is a potent PI3K inhibitor with IC50 value of 1.14 nM. COX-2/PI3K-IN-1 is a selective COX-2 inhibitor with Ki value of 3.24 nM. COX-2/PI3K-IN-1 has anti-inflammatory and anti-cancer properties.
    COX-2/PI3K-IN-1
  • HY-147912
    COX-2/PI3K-IN-2

    		PI3K COX Inflammation/Immunology Cancer
    COX-2/PI3K-IN-2 (compound 5f) is a potent PI3K inhibitor with IC50 value of 2.78 nM. COX-2/PI3K-IN-2 is a selective COX-2 inhibitor with Ki value of 3.02 nM. COX-2/PI3K-IN-2 shows anti-inflammatory and anti-cancer properties .
    COX-2/PI3K-IN-2
  • HY-150685
    Topo I/COX-2-IN-1

    		Topoisomerase Prostaglandin Receptor Apoptosis Inflammation/Immunology Cancer
    Topo I/COX-2-IN-1 (1H-30) is a potential Topo I/COX-2 inhibitor. Topo I/COX-2-IN-1 inhibits COX-2 and Topo I with the IC50 value of 0.24 μM and 4.42 μM, respectively. Topo I/COX-2-IN-1 can induce apoptosis and inhibit migration of cancer cells, has anti-cancer activity .
    Topo I/COX-2-IN-1
  • HY-146295
    COX-2/5-LOX-IN-2

    		COX Inflammation/Immunology
    COX-2/5-LOX-IN-2 (5b) is a potent and dual inhibitor of COX-2/5-LOX. COX-2/5-LOX-IN-2 is a benzothiophen-2-yl pyrazole carboxylic acid derivative. COX-2/5-LOX-IN-2 shows the most potent analgesic and anti-inflammatory activities surpassing that of Celecoxib and Indomethacin. COX-2/5-LOX-IN-2 shows potent COX-1, COX-2 and 5-LOX inhibitory activity with IC50s of 5.40, 0.01 and 1.78 μM, respectively .
    COX-2/5-LOX-IN-2
  • HY-146294
    COX-2/5-LOX-IN-1

    		COX Inflammation/Immunology
    COX-2/5-LOX-IN-1 (compound 3a) is a potent and dual inhibitor of COX-2/5-LOX. COX-2/5-LOX-IN-1 is a benzothiophen-2-yl pyrazole carboxylic acid derivative. COX-2/5-LOX-IN-1 shows the most potent analgesic and anti-inflammatory activities surpassing that of Celecoxib and Indomethacin. COX-2/5-LOX-IN-1 shows potent COX-1, COX-2 and 5-LOX inhibitory activity with IC50s of 12.13, 0.4 and 4.96 μM, respectively .
    COX-2/5-LOX-IN-1
  • HY-177319
    COX-2-IN-56

    		COX Inflammation/Immunology
    COX-2-IN-56 (example 6) is a selective COX-2 inhibitor without significantly inhibiting COX-1. COX-2-IN-56 can be used for the study of COX-2 dependent disorders, such as inflammation .
    COX-2-IN-56
  • HY-161862
    COX-2-IN-44

    		COX Inflammation/Immunology
    COX-2-IN-44 is a potent and orally active COX-2 inhibitor with IC50 values of 0.18,1.14 µM for COX-2, COX-1, respectively. COX-2-IN-44 shows anti-inflammatory activity .
    COX-2-IN-44
  • HY-163509
    COX-2-IN-43

    		COX Apoptosis Cancer
    COX-2-IN-43 (Compound MYM4) is a COX-2 inhibitor (IC50: 0.983 and 0.247 μM for COX-1 and COX-2 respectively). COX-2-IN-43 inhibits cancer cell proliferation and colonization, induces apoptosis .
    COX-2-IN-43
  • HY-150553
    COX-2-IN-28

    		COX Inflammation/Immunology
    COX-2-IN-28 is a potent and selective COX-2 inhibitor with IC50 values of 0.054, 2.14, 13.21 µM for COX-2, 15-LOX, COX-1,respectively .
    COX-2-IN-28
  • HY-150551
    COX-2-IN-27

    		COX Inflammation/Immunology
    COX-2-IN-27 is a potent and selective COX-2 inhibitor with IC50 values of 13.22, 0.045, 1.67 µM for COX-1, COX-2, 15-LOX, respectively. COX-2-IN-27 shows anti-inflammatory activity .
    COX-2-IN-27
  • HY-170932
    EGFR/COX-2-IN-1

    		EGFR COX Apoptosis Cancer
    EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor. EGFR/COX-2-IN-1 inhibits EGFR WT, EGFR T790M, COX-1 and COX-2 with IC50s of 0.12, 0.076, 20.1 and 1.52 μM respectively. EGFR/COX-2-IN-1 inhibits and with IC50s of , respectively. EGFR/COX-2-IN-1 inhibits MCF-7, HT-29 and A-549 with IC50s of 1.20, 5.14 and 14.81 μM, respectively. EGFR/COX-2-IN-1 displays Apoptosis induction by up-regulating Bax and down-regulating Bcl-2 protein levels. EGFR/COX-2-IN-1 results in a significant increase in the percentage of cells at the G2/M in MFC-7 cells. EGFR/COX-2-IN-1 exhibits broad-spectrum antitumor effects .
    EGFR/COX-2-IN-1
  • HY-147692
    COX-2-IN-14

    		COX Inflammation/Immunology
    COX-2-IN-14 (compound 2a) is a potent and selective COX-2 (cyclooxygenase-2) inhibitor. COX-2-IN-14 shows effective binding at the active site of COX-2 co-crystal. COX-2-IN-14 exhibits a high level of in vivo anti-inflammatory activity, reducing ear edema and myeloperoxidase (MPO) activity in mice .
    COX-2-IN-14
  • HY-115866
    COX-2-IN-6

    		COX Cancer
    COX-2-IN-6 (compound 10) is an orally active, gut-restricted and selective cyclooxygenase-2 (COX-2) inhibitor for colorectal Chemoprevention of cancer. COX-2-IN-6 selectively targets COX-2 with an IC50 of 0.84 μM and a Ki of 69 nM. COX-2-IN-6 also inhibits COX-2-driven PGE2 synthesis with an IC50 of 0.60 μM .
    COX-2-IN-6
  • HY-115976
    COX-2-IN-10

    		COX Inflammation/Immunology
    COX-2-IN-10 is a potent COX-2 inhibitor. COX-2-IN-10 inhibits the production of PGE2 in concentration dependent manner (IC50=2.54 µM). COX-2-IN-10 inhibits the expression of iNOS and COX-2 on mRNA and protein level . COX-2-IN-10 inhibits the production of IL-6, TNF-α and IL-1β .
    COX-2-IN-10
  • HY-179021
    COX-2/15-LOX-IN-7

    		COX Lipoxygenase Cancer
    COX-2/15-LOX-IN-7 is a potent, selective and orally active dual inhibitor of COX-2 and 15-LOX with IC50 values of 0.022 and 1.19 μM. COX-2/15-LOX-IN-7 also inhibits COX-1 with an IC50 value of 28.081μM. COX-2/15-LOX-IN-7 has low cytotoxicity against human colorectal cancer HT-29 and HCT116 cell lines (IC50 >100 μM for both). COX-2/15-LOX-IN-7 exhibits non-ulcerogenic performance. COX-2/15-LOX-IN-7 can be used for the research of cancer .
    COX-2/15-LOX-IN-7
  • HY-150721
    COX-2-IN-29

    		COX Neurological Disease Inflammation/Immunology
    COX-2-IN-29 (Compound 15b) is a selective and orally active COX-2 inhibitor with an IC50 of 0.005 μM .
    COX-2-IN-29

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: